National Hospital and CryoCord Sign MoU to Expand Access to Stem Cell Therapy in Indonesia

National Hospital Surabaya and CryoCord Indonesia today formalized a strategic collaboration through the signing of a Memorandum of Understanding (MoU) aimed at strengthening access to stem cell-based therapies while supporting the advancement of regenerative medicine in Indonesia.

The MoU signing ceremony was held at National Hospital and attended by Mr. Ang Hoey Tiong, Chief Executive Officer of National Hospital Surabaya; Alexander Ang, Chief Information Officer of National Hospital; dr. Hendera Henderi, Sp.OG, MHPM, Director of National Hospital; Mr. Daniel Limanto, representative of CryoCord Indonesia; and Mr. James Then, Managing Director of CryoCord Group.

This collaboration reflects the shared vision and commitment of both organizations to deliver stem cell therapies that are safe, ethical, and responsibly managed in accordance with applicable regulations and clinical standards. The partnership is also expected to broaden patient access to stem cell-based treatment options in various medical specialties, including orthopedics and plastic surgery, provided that all clinical indications and regulatory requirements are met.

As one of Southeast Asia's leading companies in cell and gene therapy, CryoCord Group has continuously expanded its capabilities beyond stem cell banking. Through this collaboration, CryoCord will facilitate access for clients who have stored their stem cells at its facilities, allowing eligible family members with certain medical conditions to utilize their stored stem cells, subject to clinical eligibility and approval by National Hospital's Regenerative Medicine Team. National Hospital remains committed to ensuring that all treatments are conducted under the supervision of qualified healthcare professionals while adhering to medical ethics and prevailing regulations.

During the signing ceremony, James Then, Managing Director of CryoCord Group, stated: "This collaboration represents an important milestone in realizing CryoCord's mission of bridging laboratory research with real-world clinical applications. Beyond preserving valuable biological resources such as umbilical cord tissue and cord blood stem cells, we are committed to expanding responsible access to stem cell therapies that have the potential to deliver meaningful breakthroughs for patients, both today and in the future."

The MoU marks another significant milestone in CryoCord Group's journey in cell and gene therapy. Over the years, CryoCord has evolved beyond being a stem cell banking specialist by expanding into advanced therapeutic solutions, including Natural Killer (NK) Cell Therapy, Extracellular Particles (EP), Cytokine-Induced Killer (CIK) Cell Therapy, and Chimeric Antigen Receptor (CAR) T-Cell Therapy, reflecting its commitment to advancing next-generation healthcare solutions.

By combining National Hospital's expertise in clinical healthcare services with CryoCord Group's leadership in cell and gene technologies, this partnership is expected to contribute significantly to the continued development of regenerative medicine and innovative healthcare services in Indonesia.

The collaboration also reflects National Hospital's ongoing commitment to introducing cutting-edge medical technologies, innovation, and internationally recognized healthcare services to the Indonesian community. Through the "Beyond Stem Cell Banking" event, National Hospital reaffirmed its vision of providing healthcare services driven by the latest advancements in medical technology for the benefit of its patients.

The strategic partnership with CryoCord in stem cell banking and therapy represents a concrete step toward expanding public access to advanced healthcare technologies without requiring patients to seek treatment abroad. Supported by experienced medical professionals, modern facilities, and internationally recognized standards of care, National Hospital believes that Indonesians can now receive world-class healthcare services within the country.

"As a hospital committed to delivering the latest medical technologies, innovation, and international-standard healthcare services, we continuously strive to ensure that Indonesians can access the highest quality medical care without having to travel overseas. Our collaboration with CryoCord in stem cell banking and therapy represents one of our tangible efforts to provide more advanced, preventive, and future-oriented healthcare services," said dr. Hendera Henderi, Sp.OG, MHPM, Director of National Hospital.

Looking ahead, National Hospital and CryoCord are committed to continuously introducing internationally recognized healthcare innovations while supporting the growth of Indonesia's regenerative medicine ecosystem. This collaboration is expected to become an important milestone in building a more advanced, self-reliant, and globally competitive healthcare system for Indonesia.